A new vaccine produced by AstraZeneca has begun testing at the University of Oxford in the UK. It was created to protect against the beta version of the coronavirus, which first appeared in South Africa.
It is reported by Le Figaro… The tests began on Sunday, June 27, and will involve 2,250 people from the UK, South Africa, Brazil and Poland.
Phase II and III clinical trials will be conducted in Oxford, which will show the effectiveness of the vaccine in humans.
The likely vaccine, known as AZD2816, was made using the so-called “viral vector” (adenovirus) technology that is currently being used against COVID-19 around the world.
The first test results, according to the publication, may appear as early as this year. They will be submitted to regulatory bodies for an expedited assessment.
According to Andrew Pollard, professor and director of the Oxford vaccine Group, the creation and testing of vaccines is very important in order to “stay ahead of pandemics.”
“Testing booster doses of existing vaccines and vaccines against new variants is important to ensure that we are as well prepared as possible to stay ahead of the coronavirus pandemic if their use proves necessary,” he said.
Beta (B.1.351) – South African strain of coronavirus, first discovered in South Africa, like the previous one, in December 2020.
As reported OBOZREVATEL, in the Indian strain of the coronavirus, which was given the name Delta, found two mutations… The greatest concern among physicians and scientists is now caused by the Delta Plus option, which has already been recorded in 10 countries around the world.
–
